SLNO: Urgent Action Needed – Class Action Deadline Approaches!

Soleno Therapeutics (NASDAQ: SLNO) is a clinical-stage biopharmaceutical company that recently transitioned to commercial stage with its first and only product, VYKAT™ XR (diazoxide choline), approved in March 2025 for hyperphagia in Prader-Willi syndrome (PWS) (www.globenewswire.com) (www.globenewswire.com). The company achieved initial commercial success in 2025, but is now under intense scrutiny due to safety concerns and litigation. A securities class action lawsuit has been filed on behalf of investors who purchased SLNO between March 26, 2025 (the approval date) and Nov. 4, 2025 – with a lead plaintiff filing deadline of May 5, 2026 (www.globenewswire.com) (www.globenewswire.com). This report provides a deep-dive into Soleno’s financials, capital structure, valuation, and the risks/red flags that led to these legal actions.

Dividend Policy & Capital Returns

Soleno does not pay a dividend and has no history of dividends (finance.yahoo.com). Instead, the company opted to return capital to shareholders via a large share repurchase program. In November 2025, shortly after its drug launch, Soleno’s board authorized and executed a $100 million accelerated share repurchase (ASR) – a notable move for a newly profitable biotech. Management cited confidence in VYKAT XR’s prospects and an “underappreciated” cash generation profile as reasons for the buyback (www.biospace.com). Under the ASR, Soleno paid $100M upfront and initially received ~1.51 million shares (pricing based on ~$66 per share) with the final share count to be determined by the stock’s average price over the program’s term (www.biospace.com). This one-time buyback reflects Soleno’s current capital return strategy in lieu of dividends; however, no recurring dividend has been initiated and none is expected given the company’s focus on growth and pipeline development.

Leverage and Debt Maturities

Leverage is modest for Soleno. As of year-end 2025, the company had $50 million in long-term debt outstanding (www.sec.gov) (www.sec.gov). This debt is part of a term loan agreement with Oxford Finance, which originally provided $50M (drawn) and included additional tranches of up to $100M more if certain milestones are met (an extra $50M available through Sep 2025 that was not drawn, $25M available through Sep 2026, another potential $25M upon future milestones, and a further $50M with mutual consent) (www.sec.gov). The loan is interest-only for 48 months, then amortizes. Its maturity is set for December 2029, but if Soleno hits specified milestones, the interest-only period extends 12 months and final maturity moves to December 2030 (www.sec.gov) (www.sec.gov). In either case, no principal payments are due until February 2029 (or 2030 with extension), meaning no near-term debt maturities. The loan carries a floating rate of Term SOFR + 5.5% interest (www.sec.gov), roughly ~10-11% currently, and is secured by substantially all assets (www.sec.gov). Notably, Soleno is in a net cash position – it ended 2025 with $506.1 million in cash, equivalents, and marketable securities (www.globenewswire.com), far exceeding its $50M debt. This huge cash buffer stems from a $230M equity raise in mid-2025 and positive operating cash flow from the VYKAT launch. Thus, leverage risk is low, and liquidity is strong.

One obligation to watch is a contingent milestone payment related to Soleno’s 2017 acquisition of Essentialis, the original developer of DCCR. Upon achieving certain commercial milestones for DCCR, Soleno must pay former Essentialis shareholders – as of Q4 2025, a $20.3 million contingent liability has been recognized as current, reflecting a milestone now due (www.globenewswire.com). This likely corresponds to the successful U.S. launch (the company reached profitability and ~$190M revenue in 2025). Payment of this milestone will modestly reduce cash, but is already accounted for in liabilities.

Coverage and Cash Flow

Soleno’s ability to cover its fixed charges appears very comfortable at this time. With interest-only debt and large cash reserves, interest coverage is not an issue – in fact, through 2025 the company earned substantial interest on its cash. For the nine months ended Sep 30, 2025, Soleno had $11.8M in interest income vs. $4.1M in interest expense (www.sec.gov), effectively net interest income due to its hefty cash and investments. Even after the Q4 share buyback, the year-end cash over $500M will continue to generate interest income that offsets much of the ~10% coupon on the $50M debt. The company’s first year of sales also yielded positive operating cash flow. In Q4 2025 alone, Soleno generated $48.7M of cash from operations (www.globenewswire.com) on the back of strong VYKAT XR sales, indicating that operating cash flow is covering the company’s ongoing needs (and even funding a portion of the buyback). With no dividend commitments and minimal near-term debt service, Soleno’s cash flows are largely being reinvested or held for strategic uses.

If we consider “coverage” in terms of dividend or distribution coverage, it’s not applicable here due to the absence of dividends. However, the buyback can be viewed as covered by the company’s cash generation and capital raise – Soleno essentially redeployed less than half of its 2025 financing proceeds ($100M of the $230M raised) to repurchase stock, while retaining ample liquidity. Moving forward, the sustainability of cash flow will depend on maintaining sales momentum and managing expenses as the company potentially expands internationally.

Valuation and Financial Metrics

At a current share price around $49 (early March 2026), Soleno’s market capitalization is roughly $2.6 billion (finance.yahoo.com). Considering 2025 was its first profitable year with $20.9 million in net income (www.globenewswire.com), the trailing P/E ratio is extremely high – on the order of 125× earnings. This reflects the market’s growth expectations more than current earnings. Soleno’s valuation in more relevant terms: Price-to-sales is ~14× (with $190.4M revenue in 2025 (www.globenewswire.com)), and EV/Sales about 11× after adjusting for cash. Such multiples are lofty for a drug company and imply investors are pricing in significant future growth (or were, prior to recent concerns). For context, management and analysts at the time of approval were optimistic: price targets ranged from $81 to $123 in early 2025 when the stock neared $74 (www.investing.com). Those targets presumed rapid uptake and sustained profitability.

However, recent developments cast doubt on growth projections. If VYKAT XR’s uptake slows or safety issues limit its use (discussed below), forward earnings could underperform expectations. On the other hand, if Soleno can overcome these issues, 2026 could see much higher income – for instance, doubling 2025’s revenue (to ~$380M) might yield substantially higher profit given some operating leverage. That potential keeps valuation elevated. It’s also worth noting Soleno’s enterprise value (EV) is lower than its market cap by its cash holdings (~$2.15B EV), providing some valuation cushion. Still, by traditional metrics (EV/EBITDA, P/E), Soleno is trading at rich multiples that leave little margin for error. Peer comparisons are tricky – there are few direct comps (no other approved therapy for PWS hyperphagia yet). Comparable rare-disease biopharmas with a first product often trade on sales multiples of 5–10×; Soleno’s premium likely reflects being first-to-market in a high-need indication, but it may not be sustainable if growth falters. Bottom line: SLNO’s valuation is highly contingent on VYKAT XR’s success and the company’s ability to mitigate risks.

Risks and Red Flags

Soleno now faces serious risks that have raised red flags for investors and triggered shareholder lawsuits:

– Safety Concerns & Adverse Events: The commercial rollout of VYKAT XR has been marred by safety issues. A particularly alarming event was the death of a patient on the drug, reported in Q3 2025. In September 2025, Soleno disclosed via the FDA’s adverse event reporting system that a 17-year-old male patient (with severe pre-existing conditions) died while on VYKAT XR (za.investing.com). The patient, weighing 326 lbs with a history of lymphedema and other issues, died of an apparent pulmonary embolism (za.investing.com). Soleno stated the treating physician attributed the death to other causes, and the company asserted it concurred that the death was “not related” to VYKAT XR (za.investing.com). They emphasized that PWS patients often have complex health issues and short life expectancies, implying the death could be unrelated to the drug (za.investing.com). Nonetheless, the news spooked investors – SLNO shares initially plunged ~28% intraday on Sept. 10, 2025, before recovering some losses to close about 8% down (za.investing.com). The incident underscores the potential for severe adverse events with the drug, whether or not causally linked, and the sensitivity of the market to safety signals.

– High Discontinuation Rates: Even among surviving patients, tolerability issues have emerged. Soleno’s CEO disclosed on the Q3 2025 call that about 8% of patients had discontinued VYKAT XR due to adverse effects by the end of Q3 (intellectia.ai). By year-end, the drop-out rate worsened to ~12% of patients discontinuing for side effects (www.biospace.com). This is a significant figure for a rare disease therapy – it signals that side effects (notably the drug’s known tendency to cause fluid retention/edema) are impacting real-world use. A double-digit attrition rate so early in launch raised concerns about the drug’s long-term viability, as it could curtail the addressable patient pool (fewer patients stay on therapy) and deter new prescriptions. Soleno’s management acknowledged on Nov. 4, 2025, that the widely publicized short-seller report (discussed next) and ensuing safety worries caused a “disruption in DCCR’s launch trajectory,” with slower new patient starts and higher discontinuations after the report (www.globenewswire.com).

– Short-Seller Allegations: In August 2025, Scorpion Capital, a well-known short-selling firm, published a scathing report on Soleno and VYKAT XR. Titled “Russian Roulette With Prader-Willi Children”, the report accused Soleno of pushing a “worthless, toxic drug” based on suspect trial data, and claimed the launch was one of the “worst…safety catastrophes in post-approval history” (www.globenewswire.com). It specifically alleged that Soleno’s Phase 3 trials downplayed serious safety issues like excess fluid retention in patients (www.globenewswire.com). The report even suggested VYKAT XR might be pulled from the market or see collapsing demand (rosenlegal.com). These are extraordinary claims, but they had an immediate impact: when news of Scorpion’s report hit on Aug. 15, 2025, Soleno’s stock dropped 7.4% that day and another ~4.9% the next (rosenlegal.com) (about a 12% two-day loss). The report planted early seeds of doubt about DCCR’s safety months before the official disclosures of patient death and drop-outs.

– Stock Price Collapse in Q4 2025: As the above issues came to light, Soleno’s once high-flying stock crashed. The culmination was after Q3 results on Nov. 4, 2025: despite reporting strong sales and first profits, management’s commentary on safety concerns and tempered launch outlook caused Soleno shares to plummet ~26–27% in a single day (intellectia.ai) (www.globenewswire.com) (from ~$63.85 to ~$46.87 on Nov. 5 (intellectia.ai)). In total, from its 52-week high of ~$74, SLNO lost a substantial portion of its value by late 2025. This kind of volatility and downside indicates eroded investor confidence. It’s worth noting that even a $100M buyback announcement on Nov. 11, 2025 wasn’t enough to fully stem the decline – while it signaled management’s confidence (www.biospace.com), the overriding concern remained drug safety and uptake.

– Class Action Lawsuits: The events above have led to multiple investor lawsuits. In early March 2026, at least one class action was formally filed (e.g. City of Pontiac Police & Fire Ret. Sys. v. Soleno Therapeutics in N.D. Cal.) (www.globenewswire.com), and several securities law firms (Robbins Geller, Hagens Berman, Rosen Law, Kirby McInerney, etc.) are either investigating or pursuing claims (intellectia.ai) (rosenlegal.com). The core allegation is that Soleno and its executives misled investors regarding DCCR’s safety and commercial prospects. Specifically, the class action complaint asserts that Soleno “systematically downplayed or concealed” evidence of significant safety risks (like fluid retention issues) in its Phase 3 program, resulting in the drug’s true risk profile being hidden (www.globenewswire.com). Consequently, the suit claims, DCCR’s commercial viability was overstated – the undisclosed risks (high adverse events, potential regulatory backlash, patients quitting therapy, etc.) undermined the drug’s market potential (www.globenewswire.com). Investors who purchased during the March–Nov 2025 period, relying on the company’s positive statements, suffered heavy losses when the truth emerged. The lawsuit points to the Scorpion report, the patient death 8-K, and the Q3 disclosures as corrective events that tanked the stock (www.globenewswire.com) (www.globenewswire.com). Legal risk is now a real overhang – the company could face significant litigation costs or damages, and management will be distracted addressing these allegations. Even if the suits are without merit, they underscore the reputational damage Soleno has incurred in the investment community.

– Insider Sales & Governance: A notable red flag is that insiders, including the CEO, sold shares near peak prices. On March 27, 2025 – literally the day after FDA approval – CEO Anish Bhatnagar sold ~$35.3 million worth of stock at prices ~$66–69 per share (www.investing.com) (www.investing.com). He also exercised stock options (at very low strike prices) and sold additional shares in late 2024 and early 2025 (e.g. ~$5.4M in Aug 2024, $1M in Oct 2024) (ng.investing.com). While executives often take some profit after major milestones, the magnitude and timing of Bhatnagar’s sales (just as the company entered commercialization) could be interpreted as lack of confidence in the long-term. Importantly, these sales occurred months before the safety issues became public – if management was aware of red flags from trials, it raises questions (to be clear, no direct evidence of insider wrongdoing is asserted here, but it’s a bad optic). The class action may probe whether any material adverse information was withheld during that period. At the very least, seeing the CEO cash out a large stake at all-time highs is a yellow flag for investors.

– Short Interest and Market Sentiment: SLNO has attracted significant short interest – as of the most recent data, about 8.4 million shares are sold short, roughly 19% of the float (fintel.io). A high short-interest indicates many traders are betting on further declines, likely due to the aforementioned issues. This can lead to elevated volatility (fast drops on bad news, or short-covering rallies on any optimistic development). The heavy short positioning reflects the generally bearish sentiment around Soleno’s story right now.

– Single-Product Dependence: It bears noting that Soleno’s entire fortune hinges on one product, VYKAT XR – it has no other approved drugs and only plans to repurpose DCCR for additional indications (www.globenewswire.com). This lack of diversification amplifies every risk. If VYKAT’s safety profile or efficacy in PWS is compromised, the company has no other revenue streams to fall back on. Similarly, any regulatory action (e.g. an FDA warning, label restriction, or worst-case withdrawal) would be devastating. Even absent regulatory intervention, if physicians grow reluctant to prescribe VYKAT XR due to perceived risks, sales could plateau or decline, imperiling Soleno’s financial trajectory. The company has indicated intentions to seek approval in Europe and explore DCCR in other rare diseases (www.globenewswire.com), but those initiatives are early-stage. Until another pipeline candidate emerges, Soleno is all-in on VYKAT XR, which is inherently high-risk.

In summary, Soleno is confronting a perfect storm of safety-related challenges, investor distrust, and legal battles. The rapid shift from a success story (early 2025) to a contested one (2026) highlights how critical unaddressed risks can come back to haunt a biotech. These red flags warrant close monitoring, and they help explain why shareholders have mobilized via class action.

Open Questions and Considerations

Given the above landscape, several key questions remain for Soleno’s stakeholders:

– Can the safety concerns be resolved or managed? Soleno must demonstrate that VYKAT XR’s benefits outweigh its risks. Will the discontinuation rate stabilize, or will more patients quit as time goes on? Importantly, can Soleno mitigate side effects (e.g. through dosing adjustments or monitoring) to improve tolerability? Any updates from ongoing post-marketing studies or real-world data will be crucial. Regulatory scrutiny is another factor – might the FDA impose additional warnings or requirements due to the edema and adverse events? So far the company maintains the drug’s “proven safety,” noting that PWS patients inherently have health risks (za.investing.com). Investors will be watching if that stance holds or if any safety signal causes a change in labeling or market status.

– How will commercial momentum hold up? Despite early uptake (over 1,250 patient start forms by year-end 2025, ~12.5% of the U.S. market (www.biospace.com)), recent negative publicity could hamper growth. Will new patient starts reaccelerate now that initial scare from the short report is a few months behind, or has the pool of willing prescribers shrunk? Additionally, are physicians and caregivers becoming hesitant due to the death report and side effects? Soleno reported 859 active patients on drug at end of 2025 (www.globenewswire.com) – investors will want to see that number climbing in 2026, not stalling. Reimbursement and access also tie in: Soleno achieved coverage for 185 million lives by Dec 2025 (insurance coverage) (www.globenewswire.com), which is positive, but if demand wavers, payors could question the drug’s value. In essence, the trajectory of sales in 2026 – whether the company can continue double-digit quarter-over-quarter revenue growth – is an open question that will drive valuation.

– International and Pipeline Plans: Soleno plans to pursue EU approval for DCCR and explore other rare diseases for DCCR (leveraging its mechanism) (www.globenewswire.com). How feasible is EU approval given the U.S. safety debate? European regulators may scrutinize the U.S. launch experience; any serious safety cloud could delay or derail approval in Europe. Furthermore, what additional trials or data might be needed for EU or other markets? On pipeline, Soleno has not yet announced concrete new indications – which conditions are they targeting next for DCCR? And will those require full clinical trials? The timeline and investment for these plans are unclear. In short, growth beyond the U.S. PWS market is a question mark. Successful expansion could greatly enlarge Soleno’s opportunity, but any hiccups (regulatory or scientific) would keep the company confined to a smaller revenue base.

– Financial Strategy and Cash Utilization: With $500M+ in cash, Soleno has a substantial war chest. How they deploy it is a key consideration. The share buyback was one use – but in hindsight, was that the best use of funds given the stock’s subsequent decline? Will Soleno consider another buyback to support the stock, or shift to conserving cash? Also, could Soleno use its cash for acquisitions or partnerships to diversify its portfolio (reducing single-drug risk)? Thus far, management has not announced plans for M&A. On the other hand, cash might be needed for legal liabilities if the class action or any settlements require it (though insurance often covers some). Another financial question: if VYKAT XR falters, will Soleno’s newfound profitability reverse into losses, causing cash burn? The company’s operating expenses (marketing, R&D for new indications, etc.) will be closely managed to avoid eroding the cash runway. Investors are essentially asking: is Soleno’s cash a strategic asset for growth or a buffer for potential storms? The answer depends on execution in 2026.

– Outcome of the Class Action: While legal processes can take years, the class action’s progress bears watching. An adverse outcome (e.g. if evidence shows the company indeed hid safety data) could result in significant settlements or judgments. Even if Soleno prevails, the proceedings could unease investors and limit the company’s ability to raise capital (should it need to) or depress the stock. Will any internal documents or testimony come out that shed new light on what management knew about the drug’s risks? That could influence public perception further. For now, investors with substantial losses have until May 5, 2026 to seek lead plaintiff status (www.globenewswire.com) – the level of shareholder participation might indicate how widespread the discontent is. This situation also raises governance concerns: how will Soleno’s board address the allegations? Any changes in executive leadership or additional risk oversight might result, depending on findings.

In conclusion, Soleno Therapeutics is at a crossroads. The company delivered an impressive commercial debut for VYKAT XR and proved the market demand for a PWS hyperphagia treatment (www.globenewswire.com). Yet, serious red flags around safety and transparency have prompted a sharp market reevaluation of SLNO. Investors must weigh whether the current challenges are transient issues that can be managed – or fundamental flaws that threaten the long-term story. The upcoming months (and the class action developments) should provide clarity. Shareholders are advised to stay informed and exercise their rights. Those who bought in during the hype and have since incurred losses should note the class action lead plaintiff deadline (May 5, 2026) (www.globenewswire.com) if they wish to participate in seeking recovery. Meanwhile, potential investors should remain cautious until there is better visibility on how Soleno navigates its safety issues and sustains its growth trajectory. In the high-stakes field of rare disease biotech, credibility and patient safety are paramount – Soleno’s ability to restore both will determine if the stock can regain its lost ground or if further pain lies ahead.

Sources: Soleno Therapeutics SEC filings and press releases; class action filings and law firm announcements; and reputable financial media coverage as cited throughout this report.

For informational purposes only; not investment advice.